Vismodegib is intended for use in adult patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has metastasized.
BCC is usually curable if the lesions are restricted to a small area of the skin. However, in rare cases, the lesions can become disfiguring, invade surrounding tissue, or metastasize.
A reduction or elimination of detectable cancer was observed in 43% of patients with locally advanced basal cell carcinoma and 30% of patients with metastatic basal cell carcinoma. While these stats show promise, there is always the down side with side effects such as muscle spasms, hair loss, taste disturbance, weight loss, and fatigue.